We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Extends Action Date For Astellas' Heart Drug
FDA Extends Action Date For Astellas' Heart Drug
September 7, 2007
The FDA notified Astellas Pharma U.S. and partner Cardiome Pharma that the agency action date for the firm’s investigational atrial fibrillation treatment vernakalant would be extended to Jan. 19, 2008, the companies recently announced.